Borealis Bio emerged from stealth in August 2024 with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research ...

A clinical-stage vaccine company focused on preventing and treating disease caused by Bordetella pertussis. Its lead program, BPZE1, is an intranasal live attenuated pertussis vaccine intended to ...

A pre-clinical biopharmaceutical company dedicated to precision cardiology through targeted RNA therapeutics designed to address the biologic drivers of rare, genetically driven heart diseases. Atrium ...

A biotechnology company creating therapeutics that transform diseased cells into coordinators of cure. Sonata’s machine learning-based platform takes the guesswork out of drug discovery by providing ...

A biotechnology company developing oral macrocyclic-peptide therapies designed to combine small-molecule convenience with biologic-level target specificity. Founded in 2025 and headquartered in San ...

A San Diego biotechnology company developing oral small molecule medicines for immunology, led by a selective IGF-1R inhibitor targeting thyroid eye disease, an indication currently served only by ...

US drugmaker Ironwood Pharmaceuticals, which is focused on gastrointestinal and rare diseases, has announced a leadership ...

US genetic medicines developer Estuary Biotherapeutics today announced its launch with $103 million in total committed ...

Fractyl Health today announced top-line six-month results from the Pivotal Cohort of its ongoing REMAIN-1 study (Pivotal ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines and two biosimilars ...

Belgian biotech Lakefront Biotherapeutics (Euronext: LKFT), formerly Galapagos, has sold its preclinical cell therapy ...

US healthcare investment firm OrbiMed has raised $3 billion in commitments for two funds targeting companies across the USA, ...